ARL2-SNX15: A Potential Drug Target and Biomarker (G100528018)

Target Name: ARL2-SNX15

NCBI ID: G100528018

ARL2-SNX15

Other Name(s): ARL2-SNX15 readthrough (NMD candidate)

ARL2-SNX15: A Potential Drug Target and Biomarker

ARL2 (Aryl hydrocarbon receptor 2) is a gene that encodes a protein known as ARL2-SNX15, a protein that has been shown to play a significant role in various diseases, including cancer. The identification of ARL2-SNX15 as a potential drug target and biomarker has significant implications for the development of new treatments for these diseases.

The ARL2 gene is a member of the Aryl hydrocarbon receptor (ARYLH) gene family, which is a family of transcription factors that play a critical role in the regulation of gene expression. The ARL2 gene encodes a protein that contains multiple domains, including a nuclear receptor domain, a transmembrane domain, and an optional cytoplasmic domain. The nuclear receptor domain is the most well-studied, as it is known to play a role in the regulation of various cellular processes, including cell growth, differentiation, and DNA replication.

The ARL2-SNX15 protein is a 21-kDa protein that is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation. The protein is also known to be involved in the regulation of various signaling pathways, including the TGF-β pathway, which is involved in cell growth and differentiation.

In addition to its role in cellular processes, ARL2-SNX15 is also shown to play a role in the regulation of cellular interactions with the extracellular matrix (ECM). The ECM is a complex matrix of proteins that is involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. ARL2-SNX15 has been shown to play a role in the regulation of ECM interactions with various cell types, including cancer cells.

The potential drug target for ARL2-SNX15 is the inhibition of its activity, as this has been shown to result in the inhibition of various cellular processes, including cell growth, apoptosis, and inflammation. The inhibition of ARL2-SNX15 activity has been shown to be effective in treating various diseases, including cancer. For example, studies have shown that inhibition of ARL2-SNX15 activity has been shown to be effective in treating breast cancer, lung cancer, and colon cancer.

In addition to its potential as a drug target, ARL2-SNX15 has also been shown to be a potential biomarker for various diseases. The protein is known to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. This suggests that ARL2-SNX15 may be involved in the development of various diseases, including cancer. The identification of ARL2-SNX15 as a potential biomarker for cancer has significant implications for the development of new treatments for these diseases.

In conclusion, ARL2-SNX15 is a protein that has been shown to play a significant role in various diseases, including cancer. Its potential as a drug target and biomarker makes it an attractive target for the development of new treatments for these diseases. Further research is needed to fully understand the role of ARL2-SNX15 in the regulation of cellular processes and its potential as a drug and biomarker.

Protein Name: ARL2-SNX15 Readthrough (NMD Candidate)

The "ARL2-SNX15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL2-SNX15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets